Quality of life in patients with facial steroid dermatitis before and after treatment

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 6, 2008, Pages 663-669

  Liu, Ze He ^a,b   Du, X H ^a  

^a Third Hospital of Hangzhou   (China)

^b INSTITUTE OF DERMATOLOGY   (China)

Author keywords

Doxycycline; Indomethacin; Quality of life; Steroid dermatitis

Indexed keywords

CETIRIZINE; DOXYCYCLINE; INDOMETACIN; LORATADINE; STEROID; WHITE PETROLATUM;

ADULT; ARTICLE; CHINA; CLINICAL ASSESSMENT; DERMATITIS; DRUG EFFICACY; DRY SKIN; FACE EDEMA; FACIAL STEROID DERMATITIS; FEMALE; HEALTH EDUCATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PSYCHOSOCIAL CARE; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; REBOUND; SCORING SYSTEM; SKIN BURNING SENSATION; SKIN DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; CETIRIZINE; DERMATITIS, CONTACT; DOXYCYCLINE; DRUG THERAPY, COMBINATION; FACE; FEMALE; HUMANS; INDOMETHACIN; LORATADINE; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 43649105030     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.02639.x     Document Type: Article

References (32)

1. Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952; 19: 101-102.
2. Burry JN. Topical drug addiction: Adverse effects of fluorinated corticosteroid creams and ointments. Med J Aust 1973; 1: 393-396.
3. Frumess GM, Lewis HM. Light-sensitive seborrheid. Arch Dermatol 1957; 75: 245-248.
4. Mihan R, Ayres S Jr. Perioral dermatitis. Arch Dermatol 1964; 89: 803-805.
5. Cotterill JA. Perioral dermatitis. Br J Dermatol 1979; 101: 259-262.
6. Wilkinson DS, Kirton V, Wilkinson JD. Perioral dermatitis: A 12-year review. Br J Dermatol 1979; 101: 245-257.
7. Yung A. Perioral dermatitis and inadvertent topical corticosteroid exposure. Br J Dermatol 2002; 147: 1279-1280.
8. Sneddon I. Adverse effect of topical fluorinated corticosteroids in rosacea. Br Med J 1969; 1: 671-673.
9. Leyden JJ, Thew M, Kligman AM. Steroid rosacea. Arch Dermatol 1974; 110: 619-622.
10. Rapaport MJ, Rapaport V. Eyelid dermatitis to red face syndrome to cure: clinical experience in 100 cases. J Am Acad Dermatol 1999; 41: 435-442.
11. Rapaport MJ, Lebwohl M. Corticosteroid addiction and withdrawal in the atopic: The red burning skin syndrome. Clin Dermatol 2003; 21: 201-214.
12. Halioua B, Beumont MG, Lunel F. Quality of life in dermatology. Int J Dermatol 2000; 39: 801-806.
13. Finlay AY. Quality of life measurement in dermatology: A practical guide. Br J Dermatol 1997; 136: 305-314.
14. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
15. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004; 9: 169-180.
16. Wang XL, Zhao TE, Zhang XQ. Assessment on the reliability and validity of the Dermatology Life Quality Index in Chinese version. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 791-793.
17. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-664.
18. Ljubojeviae S, Basta-Juzbasiae A, Lipozenèiae J. Steroid dermatitis resembling rosacea: Aetiopathogenesis and treatment. J Eur Acad Dermatol Venereol 2002; 16: 121-126.
19. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-15.
20. Nnoruka E, Okoye O. Topical steroid abuse: Its use as a depigmenting agent. J Natl Med Assoc 2006; 98: 934-939.
21. Chu CY. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption. J Eur Acad Dermatol Venereol 2007; 21: 484-490.
22. Chu CY. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005; 152: 396-399.
23. Al-Dhalimi MA, Aljawahiry N. Misuse of topical corticosteroids: A clinical study in an Iraqi hospital. East Mediterr Health J 2006; 12: 847-852.
24. Rogers PJ, Wood SM, Garrett EL et al. Use of nonprescription topical steroids: Patients' experiences. Br J Dermatol 2005; 152: 1193-1198.
25. Woodford R, Woodford EM, Langley CA, Marriott JF, Wilson KA. Patient knowledge and acceptability of topical corticosteroid preparations: The role of the pharmacist in patient education. Int J Pharm Pract 2001; 9 (Suppl.): R38.
26. Ellis CN, Pillitteri JL, Kyle TK, Ertischek MD, Burton SL, Shiffman S. Consumers appropriately self-treat based on labeling for over-the-counter hydrocortisone. J Am Acad Dermatol 2005; 53: 41-51.
27. Ravis SM, Eaglstein WH. Topical hydrocortisone from prescription to over-the-countAr sale: A past controversy: a cautionary tale. Arch Dermatol 2007; 143: 413-415.
28. Tackett BN, Smith MC, Nedorost ST. Morbidity of over-the-counter topical steroids. J Am Acad Dermatol 2006; 54: 182-183.
29. Kligman AM, Frosch PJ. Steroid addiction. Int J Dermatol 1979; 18: 23-31.
30. Rapaport MJ, Rapaport VH. Serum nitric oxide levels in 'red' patients: separating corticosteroid-addicted patients from those with chronic eczema. Arch Dermatol 2004; 140: 1013-1014.
31. Maroti M, Ulff E, Wijma B. Quality of life before and 6 weeks after treatment in a dermatological outpatient treatment unit. J Eur Acad Dermatol Venereol 2006; 20: 1081-1085.
32. Vensel E, Hilley T, Trent J et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol 2000; 43: 858-860.